文献速递外周血管胸部USCT

COVID-19住院患者静脉血栓栓塞症的筛查方案与患病率

Screening Protocol and Prevalence of Venous Thromboembolic Disease in Hospitalized Patients With COVID-19.
PubMed 文献 · J Ultrasound Med · 2021-10-25

单中心前瞻性观察研究纳入102例连续住院COVID-19患者,采用年龄校正D-二聚体和床旁超声(POCUS)筛查静脉血栓栓塞症(VTD),检出27例(26.5%),其中深静脉血栓17例(POCUS阳性率16.6%)、肺栓塞18例(PCTA阳性率46.2%)。D-二聚体ROC曲线AUC为0.91;D-二聚体2000-6000 ng/mL患者可从POCUS筛查中获益,≥6000 ng/mL应行POCUS和PCTA以排除DVT和PE。

要点

  • COVID-19住院患者VTD患病率达26.5%,应重视DVT和PE的筛查。
  • 年龄校正D-二聚体联合POCUS筛查策略具有高敏感度和特异度。
  • D-二聚体≥6000 ng/mL者应行POCUS和PCTA以排除DVT和PE。

关键影像表现/征象

  • VTD患者年龄更大(P < .030)、D-二聚体更高(P < .001)、ISTH评分更高(P < .001)、死亡率更高(P = .025)。
  • VTD患者与非VTD患者在炎症实验室参数及细胞因子风暴综合征(CSS)发生上无差异。

诊断标准与关键数值

  • D-二聚体ROC曲线AUC为0.91。
  • D-二聚体2000-6000 ng/mL的患者可从POCUS筛查中获益(高敏感度和特异度)。
  • D-二聚体≥6000 ng/mL的患者应行POCUS和PCTA以排除DVT和PE。

临床应用与阅片要点

  • 对COVID-19住院患者应结合年龄校正D-二聚体水平决定是否行POCUS筛查DVT。
  • D-二聚体≥6000 ng/mL时需同时行POCUS和PCTA以排除DVT和PE。

局限性

  • 单中心、前瞻性观察性研究,样本量有限(102例)。
  • 未来需更多临床试验验证筛查策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: SARS-CoV-2 disease (COVID-19) induces endothelial damage and sustained hypoxia and facilitates immobilization as factors of hypercoagulability.

OBJECTIVES: The objective of our study was to assess the prevalence of venous thromboembolic disease (VTD) in COVID-19 patients and the usefulness of VTD screening based on age-adjusted D-dimer and point-of-care ultrasound (POCUS).

PATIENTS/METHODS: We conducted a single cohort, prospective observational study in 102 consecutive hospitalized patients.

RESULTS: A total of 102 POCUS and 39 pulmonary computed tomography angiography (PCTA) were performed diagnosing 27 VTD (26.5%): 17 deep vein thrombosis (DVT) (16.6% positive POCUS) and 18 pulmonary embolism (PE) (46.2% positive PCTA). COVID-19 patients with VTD were older (P < .030), had higher D-dimer (P < .001), higher International Society on Thrombosis and Hemostasis score (P < .001), and higher mortality (P = .025). However, there were no differences in inflammatory laboratory parameters neither in the cytokine storm syndrome (CSS) development. The ROC curve for D-dimer showed an AUC of 0.91. We have evidenced that patients with D-dimer between 2000 and 6000 ng/mL could benefit from a screening strategy with POCUS given the high sensitivity and specificity of the test. Furthermore, patients with D-dimer ≥6000 ng/mL should undergo POCUS and PCTA to rule out DVT and PE, respectively.

CONCLUSIONS: In our cohort, 26.5% of the patients presented VTD. Screening strategy based on age-adjusted D-dimer and POCUS proved high sensitivity and specificity. Future trials focused on screening strategies are necessary to early detect the presence of DVT and PE and determine thromboprophylaxis strategies in patients with COVID-19.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Álvarez-Troncoso J, Ramos-Ruperto L, Fernández-Cidón P, et al. Screening Protocol and Prevalence of Venous Thromboembolic Disease in Hospitalized Patients With COVID-19. J Ultrasound Med. 2021. PMID: 34694032. doi:10.1002/jum.15850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。